The Food and Drug Administration (FDA) approved the use of semaglutide injectable (Ozempic) in the treatment of T2DM in 2017. The medication has received widespread acceptance due to its positive effects on weight loss and lowering of chronic health risks. Additionally, this medication has risen in popularity over the past few years, as many well-known actors/actresses/songwriters and more came forward, publicly sharing their weight loss journey. Conversely, the boost in popularity has also resulted in significant shortages of this medication, negatively impacting the lives of the diabetic community, local pharmacies and healthcare providers. The goal of this continuing education program is to educate and empower the healthcare provider in all aspects of this drug regimen: clinical indications, patient education, cost options, and benefit/risk analysis.
Course Publication Date:
March 12, 2024
This course is available with
NO ADDITIONAL FEE if you have an active
one year unlimited membership!
| Author: | Maureen Sullivan-Tevault RN, BSN, CEN, CDCES |
| Course No: | OZEMPIC-24 |
| Contact Hours: | 1.00 |
| Delivery Method: | Online Self Study |
| Category: | Medical & Surgical Issues
|
|
|
|
Learning Objectives
Identify the main types of diabetes and associated diagnostic testing
Describe the action of non-insulin injectable diabetes medication semaglutide
Discuss dosing guidelines, common side effects, and contraindications for semaglutide usage in persons with T2DM
Describe symptoms of gastroparesis in a person with diabetes
Discuss lifestyle behavior modification education specific to persons with diabetes
Verbalize familiarity with semaglutide patient assistance programs available
Discuss concerns over long term use of semaglutide injectable specific to the treatment of T2DM